



INTERIM REPORT Q1 2026

January – March

Table of contents

INTRODUCTION

About IDL Diagnostics	3
Events during the period	4
CEO's statement	5

FINANCIAL INFORMATION

Sales and operating profit	6
----------------------------------	---

The Group

Condensed statement of comprehensive income	8
Condensed balance sheet	9
Condensed statement of changes in equity	11
Condensed statement of cash flows	12

The Parent Company

Condensed income statement	13
Condensed balance sheet	14
Notes to the consolidated financial statements	17
Reconciliation of income statement and balance sheet	25

IR CONTACTS

Anders Hultman, CEO, e-mail: anders.hultman@idldiagnostics.com

Erika Nemeti, Communications & IR Director,
e-mail: erika.nemeti@idldiagnostics.com

All reports are published on the company's website
<https://idldiagnostics.com/investors/financial-reports/>


FINANCIAL CALENDAR

May 28, 2026: Annual General Meeting 2026

August 20, 2026: Interim Report Q2 2026

November 5, 2026: Interim Report Q3 2026

February 18, 2027: Year-End Report 2026



Cost-effective diagnostics that save lives

Early diagnosis is crucial in both cancer and infectious diseases. Disease progression must then be monitored over time so that treatment can be adjusted accordingly. Diagnostics are often vital for the patient's survival and continued quality of life. IDL Diagnostics' vision is to save more lives through better and earlier diagnostics.



IDL Diagnostics is a company active in the field of in vitro diagnostics

(IVD), with its primary focus on urology and bacteriology. The product portfolio includes easy-to-use rapid tests, laboratory assays and tests for automated platforms designed to identify serious diseases. The most important products in the company's portfolio are UBC[®] Rapid and TK 210 ELISA in urology and TUBEX[®] in bacteriology.

The Group consists of the Parent Company, IDL Diagnostics, and the subsidiaries, IDL Biotech and IDL Bioscience, with IDL Biotech conducting the operational activities.

Product development and innovative improvements, carried out in close collaboration with researchers and physicians at leading universities and hospitals, are central to IDL Diagnostics' operations and aim to enhance the potential for early disease detection. Through an agile organization, the company drives the development of new diagnostic solutions that meet the growing need for early and accurate detection. With a growing market, strong sales growth, a solid cash position and a clear strategy for innovation and expansion, IDL Diagnostics is an attractive investment in the future of precision medicine and health.

The goals going forward are to strengthen its presence in

existing markets, obtain market approvals in new priority areas and continuously develop the next generation of diagnostics. The ambition is to establish the company's diagnostics as the standard within prioritized areas. IDL Diagnostics (IDLDX) is listed on Nasdaq First North Growth Market.

More information is available at idldiagnostics.com.

Summary

THE GROUP IN BRIEF

SEK thousand	Jan–Mar 2026	Jan–Mar 2025	Jan–Dec 2025
Net sales	16,737	15,307	53,108
Operating profit/loss	1,222	–2,503	–11,996
Profit/loss for the period	1,211	–2,522	–12,151
Earnings per share, basic and diluted, SEK	0.01	–0.01	–0.05
Equity ratio, %	85.0%	83.8%	83.8%
Cash flow from operating activities	2,138	–607	–7,598
Cash flow for the period	760	–1,315	–11,210
Cash and cash equivalents	37,334	46,470	36,574
EBITDA	2,158	–1,609	–8,356

Events during the period

JANUARY – MARCH 2026

Feb 5: IDL Diagnostics formed a joint venture company with Concile GmbH.

Feb 26: The company published the 2025 Year-end Report.

Mar 5: Anders Hultman announced that he is stepping down as the company's CEO.

EVENTS AFTER THE END OF THE PERIOD

Apr 13: The Nomination Committee presented its proposal for the Board of Directors to the Annual General Meeting 2026.

Apr 15: CEO Anders Hultman presented the company at Redeye Nordic Growth Healthcare Day 2026.

Apr 22: IDL Diagnostics published the 2025 Annual Report.

Apr 29: The company issued a notice of the Annual General Meeting 2026.

HIGHLIGHTS DURING THE FIRST QUARTER

IDL forms joint venture with Concile

IDL Diagnostics, together with its long-established partner Concile GmbH, has formed a joint venture company. Through this collaboration, IDL's product portfolio will be expanded and marketed to a broader market.

Exhibitor at WHX Labs in Dubai

IDL Diagnostics participated as an exhibitor at WHX Labs in Dubai together with Concile. The main focus was on delivering multiple biomarkers across various POC readers and supporting tests for infection, cardiovascular diseases, oncology, hormones, and chronic diseases using a structured and platform-based approach.

Partner meetings and CLIA focus in China

IDL visited China to meet with CLIA partners in order to gain a better understanding of the challenges they face and how they can be supported in launching and marketing these products on the Chinese market.



A strong start to 2026

2026 has begun with another strong quarter, in which solid growth is combined with profitability, positive cash flow, and important strategic progress that strengthens IDL's international expansion.

IDL Diagnostics has kicked off 2026 with strong momentum. The first quarter marks the best in the company's history, and the clear growth trend we observed toward the end of last year has continued. It is very gratifying to deliver both a positive profit and a positive cash flow for the quarter. Order intake remains highly encouraging, and we have a clear plan to strengthen our presence in new markets and thereby increase the potential for continued growth over time.

High product demand

Net sales during Q1 amounted to SEK 16.7 million, reflecting continued strong demand for our products. Profit amounted to SEK 1.2 million and EBITDA came in at SEK 2.2 million, confirming that the business is profitable and that we have succeeded in maintaining a stable cost level. The cash flow of SEK 760 thousand strengthens our financial position and enables continued investment in development and expansion.

Broader product portfolio

Over the past year, we have focused on building a solid foundation to broaden and develop sales, both in existing and new markets. We have deepened our collaboration with Concile GmbH in the area of near-patient rapid tests, which in February led to the formation of a joint venture named Concile Global AB. Through this new company, we gain access to a significantly broader and more attractive product portfolio, which also strengthens our ability to launch our core products in new international markets.

Successful launch at WHX

Our presence at the WHX Labs exhibition in Dubai earlier this year marked the start of the launch of Concile Global AB and the new product portfolio. Our participation was a success, providing valuable contacts while confirming

that our product offering is very much in tune with the times. Follow-up on the discussions initiated during WHX is ongoing, and we hope that several of these negotiations will lead to productive business relationships in new markets.

Continued focus on automated platforms

During the first quarter, we also worked on developing sales of products used on automated platforms. In March, we visited our partners in China — Zecen, Vastec, Sysmex, and Fousun. The main purpose is to expand sales of our TPS tests, which are already on the market, while also preparing for the registration and launch of UBC and TK1 in China. Registration studies will now be conducted for these two markers.

A strong company ready for the next phase

As previously communicated, I will be stepping down from my role as CEO of IDL Diagnostics. I have had the privilege of working at the company for more than seven years, including the past five years as CEO. During this time, the company has undergone significant changes, not least through the acquisition of IDL Biotech. Sales have almost tripled over the past five years, while we have also strengthened the organization. We have furthermore expanded our product offering by establishing a company together with concile GmbH, which will play a crucial role in our ability to reach new markets. With pride and strong confidence in the company's future, I am now handing over the baton, convinced that IDL is well positioned for the next stage of its growth journey.

Anders Hultman, CEO, IDL Diagnostics

Sales and operating profit

The Group's revenue, earnings, and financial position are presented in the financial statements on pages 8–12. The Parent Company's revenue, earnings, and financial position are presented in the financial statements on pages 13–15.

JANUARY – MARCH 2026

Revenue

Revenue for the first quarter was SEK 16,737 (15,307) thousand. Oncology segment sales are driven by the UBC® Rapid product family and the bacteriology segment by our TUBEX® product. The oncology segment accounted for 49% (49%) of total revenue during the period, while the bacteriology segment accounted for 51% (51%).

Gross profit

Gross profit for the period was SEK 10,972 (8,116) thousand. The gross margin amounted to 65.6% (53.0%). Higher margin driven by increased revenue and operating leverage related to fixed production costs.

Other operating income

Other operating income mainly comprises positive foreign exchange differences in EUR and USD.

Financial items

Financial items comprise interest income on short-term investments and interest expenses related to lease liabilities. Net financial items for the quarter amounted to SEK –11 (–19) thousand.

Operating expenses

During the period, operating expenses amounted to SEK –9,899 (–9,910) thousand and were allocated as follows: selling expenses 21% (21%), administrative expenses 47% (43%) and development expenses 32% (36%).

Earnings

Earnings for the period amounted to SEK 1,211 (–2,522) thousand.

Cash flow, investments, and financial position

Cash flow from operating activities amounted to SEK 2,138 (–607) thousand in the first quarter.


Cash flow from investing activities amounted to SEK –1,379 (–707) thousand in the first quarter.

Cash flow from financing activities amounted to SEK 0 (0) thousand in the first quarter.

Liquidity and equity

As of March 31, 2026, cash and cash equivalents amounted to SEK 37,334 (46,470) thousand. An available overdraft facility amounts to SEK 3,500 thousand. As of March 31, 2026, equity amounted to SEK 149,370 (157,786) thousand.

Revenue January – March 2026



Future developments

IDL Diagnostics sees a substantial market potential for the Group's biomarkers as the global cancer diagnostics market continues to grow strongly. Forecasts indicate that the market will reach approximately USD 34.97 billion by 2034, corresponding to a compound annual growth rate (CAGR) of around 6.0% during the period 2025–2034.

Several independent industry assessments also confirm stable to strong expansion within in vitro diagnostics (IVD) in oncology, where biomarkers play an increasingly central role. Increased use of biomarkers strengthens both screening, risk stratification and the potential for earlier interventions. Drivers such as an aging global population, increased investments in healthcare and prevention, and rapid technological development further reinforce the need for advanced yet user-friendly diagnostics.

At the same time, healthcare systems are seeking methods that are more patient-friendly, cost-effective and easier to implement in everyday clinical practice. Here, IDL Diagnostics offers tests that can streamline monitoring and follow-up compared with traditional working methods. By combining clinical

benefit with improved accessibility, the Group's products contribute to higher quality across care pathways while addressing a rapidly growing global need.

Significant risks and uncertainties

No significant change in material risks or uncertainties has occurred during the period. The risks remain unchanged compared with the description of IDL Diagnostics' risks, uncertainties and their management presented in the company's 2025 annual report.

The share

IDL Diagnostics AB (publ) has been listed on Nasdaq First North Growth Market Sweden under IDLDX since June 30, 2016. Certified Adviser: Redeye Nordic Growth AB. Certifiedadviser@redeye.se, +46 (0)8 121 576 90. As of March 31, 2026, the number of shares totaled 230,361,066 (quotient value SEK 0.10).

Accounting policies

The consolidated financial statements have been prepared in accordance with the Swedish Annual Accounts Act, RFR 1

Supplementary Accounting Rules for Groups, and International Financial Reporting Standards (IFRS) and interpretations issued by the IFRS Interpretations Committee (IFRS IC) as adopted by the EU. The interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. The consolidated financial statements have been prepared under the historical cost convention.

Review of the report

This interim report has not been reviewed by the Parent Company's auditor.

Contact details

CEO: Anders Hultman, anders.hultman@idldiagnostics.com, 08-799 67 54

Visiting address: Karlsbodavägen 39, 168 67 Bromma, Stockholm

Corporate identity number: 556596-6107

www.idldiagnostics.com

BOARD OF DIRECTORS

Stockholm, May 12, 2026

Max Pihlqvist
Chairman

Eva Nordström
Member

Agneta Tufvesson Alm
Member

Clas Runnberg
Member

Per-Anders Abrahamsson
Member

Anders Hultman
CEO

THE GROUP

Condensed statement of comprehensive income

SEK thousand	Note	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Net sales	4	16,737	15,307	53,108
Cost of goods sold		-5,765	-7,191	-25,391
Gross profit		10,972	8,116	27,718
Selling expenses		-2,043	-2,042	-7,841
Administrative expenses		-4,653	-4,265	-17,010
Research and development expenses		-3,203	-3,604	-13,594
Other operating income		496	24	304
Other operating expenses		-347	-733	-1,573
Total operating expenses		-9,750	-10,619	-39,714
Operating profit/loss		1,222	-2,503	-11,996
Finance income		102	96	290
Finance costs		-113	-116	-445
Financial items – net		-11	-19	-155
Profit/loss before tax		1,211	-2,522	-12,151
Income tax		0	0	0
Profit/loss for the period		1,211	-2,522	-12,151

There are no items recognized in other comprehensive income; therefore, total comprehensive income corresponds to profit for the period. Profit for the period and total comprehensive income for the period are wholly attributable to the Parent Company's shareholders.

EARNINGS PER SHARE

SEK	Note	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Weighted average number of shares, basic	6	230,361,066	230,361,066	230,361,066
Weighted average number of shares, diluted		235,361,066	235,361,066	235,361,066
Earnings per share, basic and diluted		0.01	-0.01	-0.05

The notes on pages 17 to 24 form an integral part of these consolidated financial statements.

THE GROUP

Condensed balance sheet

SEK thousand	Note	March 31, 2026	March 31, 2025	Dec 31, 2025
ASSETS				
Non-current assets				
Goodwill		98,994	98,994	98,994
Other intangible assets		6,631	5,702	6,247
Property, plant and equipment		1,890	1,967	1,825
Right-of-use assets		12,475	14,852	13,070
Financial assets		50	0	0
Total non-current assets		120,041	121,515	120,135
Current assets				
Inventories		7,606	6,281	6,688
Accounts receivable		8,498	10,061	10,826
Current tax asset		523	536	1,094
Other receivables		673	621	627
Prepaid expenses and accrued income		1,151	1,101	917
Cash and cash equivalents		37,334	46,470	36,574
Total current assets		55,787	65,071	56,727
TOTAL ASSETS		175,828	186,586	176,862

The notes on pages 17 to 24 form an integral part of these consolidated financial statements.

Condensed consolidated balance sheet, cont'd

SEK thousand	Note	March 31, 2026	March 31, 2025	Dec 31, 2025
EQUITY AND LIABILITIES				
Equity		149,370	157,786	148,157
Liabilities				
Non-current liabilities				
Lease liability		10,456	12,687	11,039
Total non-current liabilities		10,465	12,697	11,039
Current liabilities				
Lease liability		2,233	2,093	2,197
Accounts payable		4,209	4,380	5,758
Other current liabilities		1,546	1,460	1,640
Accrued expenses and deferred income		8,005	8,170	8,072
Total current liabilities		15,992	16,102	17,666
Total liabilities		26,457	28,799	28,705
TOTAL EQUITY AND LIABILITIES		175,828	186,586	176,862

THE GROUP

Condensed statement of changes in equity

SEK thousand	Note	Share capital	Other contributed capital	Other capital incl. profit for the period	Total
Opening balance as of January 1, 2025		23,036	441,008	-303,735	160,309
Profit for the period and total comprehensive income				-2,522	-2,522
Closing balance as of March 31, 2025		23,036	441,008	-306,258	157,786
Opening balance as of January 1, 2026		23,036	441,008	-315,887	148,157
Profit for the period and total comprehensive income				1,211	1,211
Closing balance as of March 31, 2026		23,036	441,008	-314,673	149,370

The notes on pages 17 to 24 form an integral part of these consolidated financial statements.

THE GROUP

Condensed statement of cash flows

SEK thousand	Note	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Cash flow from operating activities				
Cash flow from operating activities before changes in working capital		1,578	-1,134	-7,430
Cash flow from changes in working capital		560	526	-168
Cash flow from operating activities		2,138	-607	-7,598
Cash flow from investing activities		-1,379	-707	-3,613
Cash flow from financing activities		0	0	0
Cash flow for the period		760	-1,315	-11,210
Cash and cash equivalents at the beginning of the period		36,574	47,785	47,785
Cash and cash equivalents at the end of the period		37,334	46,470	36,574
Notes to the statement of cash flows				
Interest received		102	96	290
Interest paid		-103	-115	-9

The notes on pages 17 to 24 form an integral part of these consolidated financial statements.

PARENT COMPANY

Condensed income statement

SEK thousand	Note	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Net sales		1,724	1,500	5,972
Cost of goods sold		-20	-131	-161
Gross profit		1,705	1,369	5,811
Selling expenses		-74	-30	-1,074
Administrative expenses		-1,924	-2,295	-8,584
Research and development expenses		-192	-214	-1,275
Other operating income		1	0	1
Other operating expenses		-4	0	-3
Total operating expenses		-2,194	-2,539	-10,935
Operating profit/loss		-489	-1,170	-5,124
Other interest income and similar items		101	95	270
Interest expenses and similar items		-10	0	-5
Total financial items – net		91	95	265
Profit/loss after financial items		-398	-1,075	-4,858
Tax on profit for the year		0	0	0
Profit/loss for the period		-398	-1,075	-4,858

The notes on pages 17 to 24 form an integral part of these consolidated financial statements.

PARENT COMPANY

Condensed balance sheet

SEK thousand	Note	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025
ASSETS				
Non-current assets				
Intangible assets		1,083	780	1,074
Property, plant and equipment		66	95	73
Financial assets		190,866	190,916	190,916
Total non-current assets		192,015	191,792	192,064
Current receivables				
Receivables from Group companies		0	0	1,867
Current tax asset		131	128	178
Other receivables		0	71	0
Prepaid expenses and accrued income		500	605	291
Total current receivables		632	804	2,336
Cash and bank balances		34,183	43,490	33,529
Total current assets		34,814	44,294	35,865
TOTAL ASSETS		226,829	236,086	227,928

Parent company condensed balance sheet, cont'd

SEK thousand	Note	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025
EQUITY				
Restricted equity		23,036	23,036	23,036
Unrestricted equity		195,741	199,922	196,139
Total equity		218,777	222,959	219,175
LIABILITIES				
Current liabilities				
Accounts payable		317	468	631
Liabilities to group companies		5,776	10,900	5,776
Other current liabilities		580	838	564
Accrued expenses and deferred income		1,379	921	1,782
Total current liabilities		8,052	13,127	8,753
Total liabilities		8,052	13,127	8,753
TOTAL EQUITY AND LIABILITIES		226,829	236,086	227,928

The notes on pages 17 to 24 form an integral part of these consolidated financial statements.

SHARE

List of largest shareholders as of March 31, 2026

Name	Holdings	Votes
Labex Holding AB	42,277,632	18.35%
Avanza Pension	23,484,236	10.19%
Jon Eiken	8,976,248	3.90%
Nordnet Pensionsförsäkring	6,460,068	2.80%
Mikael Jacobsson	4,433,003	1.92%
Gunvald Berger	3,724,237	1.62%
Didrik Hamilton	3,110,913	1.35%
Gerhard Dal	3,000,000	1.30%
Lars Axelsson	2,341,707	1.02%
Tommy Ure	2,300,000	1.00%
Total of the 10 largest shareholders	100,108,044	43.45%

Notes to the consolidated financial statements

CONTENTS

Note 1	General information.....	17
Note 2	Summary of significant accounting policies.....	17
Note 3	Critical accounting estimates and judgments.....	17
Note 4	Segment information and disclosures of net sales.....	18
Note 5	Related party transactions.....	19
Note 6	Earnings per share.....	19
Note 7	Events after the interim period.....	20
Note 8	Effects of transition to International Financial Reporting Standards (IFRS).....	20

NOTE 1 GENERAL INFORMATION

This interim report covers the parent company IDL Diagnostics AB (publ) (IDL), corporate identity number 556596-6107 and its subsidiaries. IDL is a Parent Company registered in Sweden, with its registered office in Stockholm at Karlsbodavägen 39, SE-168 67 Bromma, Sweden.

Unless otherwise stated, all amounts are presented in SEK thousand. Figures in parentheses refer to the comparative year.

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Group's interim report has been prepared in accordance with IAS 34, Interim Financial Reporting. The Parent Company applies Recommendation RFR 2 issued by the Swedish Financial Reporting Board. Except as otherwise stated below, the Group applies the same accounting policies as in the most recent annual report. Significant accounting and measurement principles are set out on pages 38–41 of the 2025 annual report. No new or amended standards effective from 1 January 2026 have had any material impact on the Company's financial reporting.

NOTE 3 CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS

The Group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the actual outcome. Estimates and assumptions that involve a significant risk of causing material adjustments to the carrying amounts of assets and liabilities within the next financial year are summarized below.

Impairment testing of goodwill

The Group tests goodwill annually for impairment in accordance with the accounting policy described in Note 2. The recoverable amount for the cash-generating units has been determined by calculating value in use. The calculation requires the use of certain estimates. The calculation is based on cash flow projections derived from budgets approved by management for the next five years. Cash flows beyond the five-year period are extrapolated using a growth rate of 3% (September 30, 2024: 3%, 2024-01-01: 3%). The growth rate applied is consistent with industry forecasts. For each cash-generating unit to which a significant amount of goodwill has been allocated, the key assumptions used in calculating value in use are presented below.

- Pre-tax discount rate
- Long-term growth rate

Key estimates and judgments regarding the lease term:

When determining the lease term, management considers all available information that provides an economic incentive to exercise an extension option or not to exercise a termination option. Extension options are included in the lease term only if it is reasonably certain that the lease will be extended (or not terminated). Possible future cash flows have not been included in the lease liability as it is not reasonably certain that the leases will be extended (or not terminated). The assessment is revised if a significant event or change in circumstances occurs that affects this judgment and the change is within the lessee's control.

Impairment testing of investments in subsidiaries in the Parent Company

Each year, the Parent Company assesses whether there is any indication that investments in subsidiaries may be impaired. The assessment is performed in accordance with the same principles as the impairment testing for goodwill.

NOTE 4 SEGMENT INFORMATION AND DISCLOSURES OF NET SALES

The Group's chief operating decision-maker is the CEO, who uses profit before tax when assessing the performance of the operating segments.

The Group's operations are managed and reported based on two reportable segments; other business activities, which generate revenue from antibodies and accessories, are presented under "Other segments":

1. Oncology: Production and sale of in vitro diagnostics for cancer diseases with UBC[®] Rapid and TK 210 ELISA as the segment's main products.
2. Bacteriology: Production and sale of in vitro diagnostics for infectious diseases with TUBEX as the segment's main product.
3. Other segments – The segment refers to a collection of smaller revenue areas not related to the company's operations in oncology or bacteriology.

Inter-segment sales are made on an arm's length basis and are eliminated on consolidation.

The amounts reported to Other segments with respect to segment revenue are measured in a manner consistent with the financial statements.

SEK thousand	January 1 – March 31, 2026					January 1 – March 31, 2025				
	Oncology	Bacteriology	Other segments	Group-wide	Total	Oncology	Bacteriology	Other segments	Group-wide	Total
Revenue by segment	8,126	8,599	36		16,737	7,555	7,745	7		15,307
Revenue from other segments					0					0
Net sales	8,126	8,599	12	0	16,737	7,555	7,745	7	0	15,307
Europe	7,567		6		7,573	7,384		3		7,387
Asia	492	8,599	6		9,098	50	7,685	4		7,739
Americas	66				66	79				79
MEA	0				0	42	60			102
Africa					0					0
Total	8,126	8,599	12	0	16,303	7,555	7,745	7	0	15,307
Profit/loss before tax	6,083	4,877	12	-9,716	1,257	4,354	3,761	1	-10,640	-2,522
Of which										
Cost of goods sold	-2,012	-3,691			-5,704	-3,172	-3,955	-6	0	-7,132
Selling expenses				-2,098	-2,098				-1,957	-1,957
Administrative expenses				-4,674	-4,674				-4,179	-4,179
Research and development expenses				-3,011	-3,011				-3,518	-3,518
Other operating income				496	496				24	24
Other operating expenses				-346	-346				-733	-733
Depreciation, amortization and impairment	-31	-31	0	-280	-341	-29	-29	0	-258	-316
Interest income				496	496				96	96
Interest expenses				-346	-346				-116	-116
Total expenses	-2,043	-3,722	0	-9,762	-15,527	-3,201	-3,984	-6	-10,640	-17,831
Profit/loss before tax	6,083	6,877	12	-9,762	1,211	4,354	3,761	1	-10,640	-2,522

NOTE 5 RELATED PARTY TRANSACTIONS

IDL Diagnostics AB (publ) is the ultimate parent company that prepares consolidated financial statements. No single party has a controlling or significant influence over IDL Diagnostics AB (publ). Related parties are all subsidiaries of the Group and key management personnel of the Group and their close family members. Transactions are conducted on arm's length terms. The following transactions have been carried out with related parties:

	2026 Jan – Mar	2025 Jan–Mar	2025 Jan–Dec
Purchase of goods and services			
Svenska Labex AB		262	0
Labex Reagens AB		43	0
Total		305	0

NOTE 6 EARNINGS PER SHARE

Earnings per share are calculated by dividing the profit for the year by the weighted average number of ordinary shares outstanding during the period.

SEK	Jan–Mar 2026	Jan–Mar 2025	Jan–Dec 2025
Earnings per share, basic	0.01	–0.01	–0.05
Earnings per share, diluted	0.01	–0.01	–0.05
Performance measures used in the calculation of earnings per share			
Profit attributable to the Parent Company's shareholders used in the calculation of earnings per share, basic and diluted	1,257,278	–2,522,313	–12,151,247
Profit attributable to the Parent Company's shareholders, SEK thousand	1,257	–2,522	–12,151
Calculation of weighted average number of shares			
Weighted average number of ordinary shares used in the calculation of earnings per share, basic	230,361,066	230,361,066	230,361,066
Adjustment for calculation of earnings per share, diluted:			
– Warrants	5,000,000	5,000,000	5,000,000
Weighted average number of ordinary shares and potential ordinary shares used as the denominator in the calculation of earnings per share, diluted	235,361,066	235,361,066	235,361,066

NOTE 7 EVENTS AFTER THE INTERIM PERIOD

Apr 13: The Nomination Committee presented its proposal for the Board of Directors to the Annual General Meeting 2026.

Apr 15: CEO Anders Hultman presented the company at Redeye Nordic Growth Healthcare Day 2026.

Apr 22: IDL Diagnostics published the 2025 Annual Report.

Apr 29: The company issued a notice of the Annual General Meeting 2026.

NOTE 8 EFFECTS OF TRANSITION TO INTERNATIONAL FINANCIAL REPORTING STANDARDS (IFRS)

The interim report as of March 31, 2026, is IDL's third financial report prepared in accordance with IFRS. The accounting policies presented in Note 2 have been applied in preparing the Group's financial statements as of March 31, 2026, and for the comparative information presented as of March 31, 2025, as well as in preparing the opening statement of financial position as of January 1, 2024 (the Group's transition date to IFRS). When preparing the opening balance sheet as of January 1, 2024, and the balance sheets as of December 31, 2024, in accordance with IFRS, amounts previously reported in the annual and interim reports under the Swedish Accounting Standards Board's general advice BFNAR 2012:1 Annual Accounts and Consolidated Financial Statements (K3) were adjusted. An explanation of how the transition from previously applied accounting standards to IFRS has affected the Group's financial position and performance is presented in the tables below and in the accompanying notes.

Elections made on transition to IFRS reporting

The transition to IFRS has been accounted for in accordance with IFRS 1 First-time Adoption of International Financial Reporting Standards. The general rule is that all applicable IFRS and IAS standards effective and approved by the EU shall be applied retrospectively. However, IFRS 1 includes certain transition provisions that allow limited exemptions from full retrospective application.

The following IFRS-permitted exemptions from full retrospective application of all standards have been applied by the company on transition from previously applied accounting standards to IFRS.

Leases

The Group has elected the exemption to apply IFRS 16 prospectively from the transition date (January 1, 2024) in accordance with IFRS 1. Under this exemption, the lease liability is measured at the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate. The right-of-use asset is measured at an amount equal to the lease liability. Furthermore, the Group has made the following elections under IFRS 1 at the transition date:

- Lease agreements for which the underlying asset is of low value are not recognized as right-of-use assets or lease liabilities.
- Hindsight has been used in determining the lease term when the contract contains options to extend or terminate the lease.

Exemption for business combinations

IFRS 1, which governs how a transition to IFRS is made, provides the option to apply the principles in IFRS 3 Business Combinations either prospectively from the transition date to IFRS or from a specific date prior to the transition date. This exemption offers relief from a full retrospective application that would otherwise require the restatement of all

business combinations occurring before the transition date. The Group has elected to apply IFRS 3 prospectively to business combinations occurring after the transition date to IFRS. Business combinations that occurred before the transition date have therefore not been restated.

Reconciliation between previous GAAP and IFRS

In accordance with IFRS 1, the Group is required to present a reconciliation between equity and total comprehensive income reported under previous GAAP and the corresponding amounts under IFRS. The Group's transition to IFRS reporting has had no effect on total cash flows from operating, investing, or financing activities. However, a reclassification of cash flows has occurred between financing activities and operating activities, as repayments of lease liabilities are reported within financing activities after the transition to IFRS. Under the previously applied accounting standards, total cash flow from leases was reported within operating activities. The tables below present the reconciliation between previously applied accounting standards and IFRS for each period, showing equity and total comprehensive income.

Reconciliation of total comprehensive income January 1 – March 31, 2025

SEK million	January 1 – March 31, 2025			
	Notes	Income statement in accordance with previous accounting framework	Total effect of IFRS transition	According to IFRS
Net sales		15,307,431	0	15,307,431
Cost of goods sold		-12,151,105	4,959,963	-7,191,142
Gross profit		3,156,326	4,959,963	8,116,289
Selling expenses		-4,515,252	2,473,676	-2,041,576
Administrative expenses		-4,277,616	12,611	-4,265,005
Research and development expenses		-6,077,257	2,473,676	-3,603,581
Other operating income		23,942	0	23,942
Other operating expenses		-732,974	0	-732,974
Total operating expenses		-15,579,157	4,959,963	-10,619,194
Operating profit/loss		-12,422,831	9,919,926	-2,502,905
Financial items – net				
Finance income		96,446	0	96,446
Finance costs		-860	-114,994	-115,854
Financial items – net		95,586	-114,994	-19,408
Profit/loss before tax		-12,327,245	9,804,931	-2,522,313
Income tax		0	0	0
Profit/loss for the year		-12,327,245	9,804,931	-2,522,313

There are no items recognized in other comprehensive income; therefore, total comprehensive income corresponds to profit for the year.

Profit for the year and total comprehensive income for the year are wholly attributable to the Parent Company's shareholders.

Reconciliation of equity as of March 31, 2025

SEK million	Notes	March 31, 2025		
		According to previous accounting framework	Total effect of IFRS transition, excluding reclassifications	According to IFRS
ASSETS				
Non-current assets				
Intangible assets				
Goodwill		49,520,517	49,473,518	98,994,035
Capitalized development costs		4,921,291	0	4,921,291
Patent		0	0	0
Other intangible assets		780,460	0	780,460
Total intangible assets		55,222,268	49,473,518	104,695,786
Property, plant and equipment				
Right-of-use assets		0	14,851,748	14,851,748
Machinery and other technical equipment		1,871,804	0	1,871,804
Equipment, tools and installations		95,446	0	95,446
Total property, plant and equipment		1,967,250	14,851,748	16,818,998
Current assets				
Inventories		6,281,434	0	6,281,434
Current receivables				
Accounts receivable		10,060,912	0	10,060,912
Current tax asset		536,178	0	536,178
Other receivables		621,392	0	621,392
Prepaid expenses and accrued income		1,720,414	-619,292	1,101,122
Cash and cash equivalents		46,469,888	0	46,468,888
TOTAL ASSETS		59,408,783	-619,292	58,789,491

There are no items recognized in other comprehensive income; therefore, total comprehensive income corresponds to profit for the year.

Profit for the year and total comprehensive income for the year are wholly attributable to the Parent Company's shareholders.

Reconciliation of equity as of March 31, 2025 cont'd

SEK million	March 31, 2025			
	Notes	According to previous accounting framework	Total effect of IFRS transition, excluding reclassifications	According to IFRS
EQUITY AND LIABILITIES				
Equity				
Share capital		23,036,106	0	23,036,106
Other contributed capital		441,007,950	0	441,007,950
Retained earnings (Including profit for the year)		-355,173,790	48,915,954	-306,257,836
Equity attributable to the Parent Company's shareholders		108,870,267	48,915,954	157,786,220
Total equity		108,870,267	48,915,954	157,786,220
Non-current liabilities				
Lease liability, non-current		0	12,697,330	12,697,330
Current liabilities				
Lease liability, current		0	2,092,691	2,092,691
Accounts payable		4,379,508	0	4,379,508
Other current liabilities		1,459,643	0	1,459,643
Accrued expenses and deferred income		8,170,317	0	8,170,317
Total current liabilities		14,009,468	2,092,691	16,102,159
Total liabilities		14,009,468	14,790,020	28,799,488
TOTAL EQUITY AND LIABILITIES		122,879,735	63,705,974	186,585,709

Explanation of the tables above

a) Reversal of goodwill amortization

Under the previously applied accounting standards, goodwill was amortized over the period during which it was expected to generate economic benefits. Under IFRS, goodwill is not amortized but is instead tested annually for impairment. As goodwill is not amortized under IFRS, the amortization of goodwill recognized under previous GAAP has been reversed with effect from January 1, 2024. Amortization of goodwill recognized during the 2025 financial year, totaling SEK 39,579 thousand, has been reversed—SEK 19,789 thousand in cost of goods sold, SEK 9,895 thousand in selling expenses, and SEK 9,895 thousand in research and development expenses—in the statement of comprehensive income, and the goodwill line item in the balance sheet has been increased accordingly. For the period January 1 to March 31, 2025, the reversal totaled SEK 9,895 thousand, of which SEK 4,947 thousand was recognized against cost of goods sold, SEK 2,474 thousand against selling expenses, and SEK 2,474 thousand against research and development expenses.

b) Leases

At the IFRS transition date, the Group recognized a right of use asset and a lease liability in the balance sheet for lease agreements that, under previously applied accounting standards, had been classified as operating leases and that did not relate to low value assets or short term leases. At the transition date to IFRS (January 1, 2024), a lease liability was recognized, measured at the present value of remaining lease payments, amounting to SEK 17,221 thousand, and to SEK 14,790 thousand as of March 31, 2025. Right of use assets were measured at the transition date at an amount equal to the value of the lease liability, adjusted for prepaid lease payments. Right of use assets amounted to SEK 17,822 thousand as of the transition date January 1, 2024, and SEK 14,852 thousand as of March 31, 2025.

In the statement of comprehensive income, right of use assets are depreciated on a straight line basis over the lease term, and interest is recognized on the lease liability using a fixed rate applied to the liability recognized for each respective period. In the statement of comprehensive income,

depreciation of right of use assets is recognized in cost of goods sold and administrative expenses, while interest expense is recognized in finance costs, instead of lease expenses previously recognized in cost of goods sold and administrative expenses. Lease expenses amounted to SEK 619 thousand for the period January 1 to March 31, 2025, and SEK 2,477 thousand for the 2025 financial year. Lease expenses were allocated evenly between cost of goods sold and administrative expenses. Depreciation of right of use assets amounted to SEK 594 thousand for the period January 1 to March 31, 2025, and SEK 2,376 thousand for the 2025 financial year. Depreciation was allocated evenly between cost of goods sold and administrative expenses. Interest expense amounted to SEK 115 thousand for the period January 1 to March 31, 2025, and SEK 437 thousand for the 2025 financial year.

c) Reclassifications and relabelings in the balance sheet and statement of comprehensive income

Balance sheet

Reclassifications and relabelings have been made for the following items in the balance sheet: "Cash and bank balances" is now presented as "Cash and cash equivalents".

Statement of comprehensive income

Reclassifications and relabelings have been made for the following items in the statement of comprehensive income: "Total result from financial investments" is now presented as "Financial items – net". Furthermore, "Tax on profit for the year" is now referred to as "Income tax" in accordance with IFRS.

Compared with the previously applied accounting standards, IFRS introduces items that should be recognized in other comprehensive income in connection with the income statement. As IDL has no items recognized in other comprehensive income, the statement has not been presented separately. These two components are presented by IDL as a single statement referred to as the "Statement of comprehensive income".

Effects of transition to RFR 2

The year-end report as of March 31, 2026 was the company's third financial report prepared in accordance with RFR 2 Accounting for Legal Entities. The accounting policies presented in Note 2 have been applied in preparing the company's financial statements as of March 31, 2026, and for the comparative information presented as of December 31, 2025, as well as in preparing the statement of financial position at the date of transition (the opening balance sheet) as of January 1, 2024. An explanation of how the transition from previously applied accounting standards to RFR 2 has affected the company is presented below.

Elections made on transition to RFR 2 reporting

The transition to RFR 2 is accounted for in accordance with IFRS 1 First-time Adoption of International Financial Reporting Standards. The general rule is that all applicable IFRS and IAS standards that have come into effect and been approved by the EU as of September 30, 2025, with the exceptions described in RFR 2 Accounting for Legal Entities, shall be applied retrospectively. However, IFRS 1 includes certain transition provisions that allow limited exemptions from full retrospective application.

In accordance with RFR 2, the company has elected to apply the following applicable exemptions:

- not to apply IFRS 9, instead measuring financial instruments in accordance with the Swedish Annual Accounts Act (ÅRL);
- not to apply IFRS 16, and to continue recognizing lease contracts as operating leases.

Reconciliation between previously applied accounting standards (K3) and RFR 2

On first-time adoption of RFR 2, the company is required to present a reconciliation between equity and total comprehensive income reported under the previously applied accounting standards and the corresponding amounts under RFR 2. The transition from the previously applied accounting standards to RFR 2 has had no effect on the income statement, balance



Visiting address: Karlsbodavägen 39, Bromma, Stockholm

Postal address: P.O Box 11151, SE-161 11 Bromma

Email: info@idldiagnostics.com

Telephone number: +46 8-799 67 50

URL: www.idldiagnostics.com

Corporate identity number: 556596-6107

